Companies

0

Speakers

0

Seats

0

Investors

0

Partners

0

Precision Medicine Community United

AAPM is on the mission to unite the precision medicine community. The 2021 Annual Meeting is bringing together, scientists, clinicians, patient advocates, entrepreneurs, investors, industry executives as well as other precision medicine experts, to share their insights. AAPM2021 is also designed to facilitate a dialogue between the 4-P’ of precision medicine: Patients, providers, public health planers (Government) and payers to work together to achieve the goal of delivering improved outcomes at reduced costs. The conference is also designed to set the research and development goals for the international precision medicine community.

REGISTER NOW
Precision Medicine Community United

AAPM Believes that

• Precision medicine field will transform our healthcare sector in the next decade and will play a crucial role in US as well as the global economy.
• Promoting a cross talk between technology & healthcare sectors will accelerate innovation.
• Showcasing successful companies/institutions, leaders/executives, with a well-deserved recognition, will boost stake holder confidence to perform better.
• Sharing best practices, case studies, and research findings will benefit the community.
• By helping precision medicine field grow and prosper, AAPM will market United States as an investment hub for the rest of the world.

REGISTER NOW
AAPM Believes that

Who’s Speaking

AAPM Past Speakers (2021 Speakers Coming Soon)

Shweta Singh ManiarGlobal Healthcare & Life Sciences Leader, Google

At Google Cloud, Shweta is the strategic client lead responsible for Healthcare and Life Sciences. Shweta has quickly risen through the ranks as a well-known innovator, game-changer, and relationship ambassador. With 18+ years’ experience in clinical research, Healthcare and Bio Tech, she has proven time and time again how valuable relationships can be by enabling dozens of start-up firms with access to capital from Federal grants and VC firms alike. She brings an eye for detail, winning contract negotiations, and financial insight to support her commercial partnership strategy expertise. A position was created just for her, after excelling in a Commercial Partnering and Strategy role at Genentech. She has been the recipient of multiple awards at Genentech, including two “Innovation Awards,” “MVP Award,” and more. Shweta brings an impressive network of established healthcare system relationships across Digital Health & Technology, Investor, Pharmaceutical, Medical Device, and Hospital Systems Industries. She is passionate about keeping current with trends in medical devices, data, wearables, IoT, EHR, and machine learning. Since joining Google, Shweta develops and manages a variety of customer and partnership relationships while identifying new opportunities.

Shweta Singh ManiarGlobal Healthcare & Life Sciences Leader, Google

At Google Cloud, Shweta is the strategic client lead responsible for Healthcare and Life Sciences. Shweta has quickly risen through the ranks as a well-known innovator, game-changer, and relationship ambassador. With 18+ years’ experience in clinical research, Healthcare and Bio Tech, she has proven time and time again how valuable relationships can be by enabling dozens of start-up firms with access to capital from Federal grants and VC firms alike. She brings an eye for detail, winning contract negotiations, and financial insight to support her commercial partnership strategy expertise. A position was created just for her, after excelling in a Commercial Partnering and Strategy role at Genentech. She has been the recipient of multiple awards at Genentech, including two “Innovation Awards,” “MVP Award,” and more. Shweta brings an impressive network of established healthcare system relationships across Digital Health & Technology, Investor, Pharmaceutical, Medical Device, and Hospital Systems Industries. She is passionate about keeping current with trends in medical devices, data, wearables, IoT, EHR, and machine learning. Since joining Google, Shweta develops and manages a variety of customer and partnership relationships while identifying new opportunities.

closepopup
Prasun Mishra, PhDFounder, CEO, AAPM, Founder, Agility Pharma & MetaImmune Inc.

Dr. Mishra (Ex-Genentech, Ex-NCI, Ex-NIH) is the Founder and CEO of Agility Pharmaceuticals, a pharmaceutical company committed to revolutionizing drug discovery & development through technology, big data, robotics, and artificial intelligence. He is a serial entrepreneur who founded his first company after graduating high school, and second company during his PhD. Since then, he has accumulated a wealth of experienced by building, investing and advising numerous other companies. He is an investor/co-founder/board member of a few US based corporations focused on accelerating drug discovery & development, blockchain and digital health. Dr. Mishra is also founding president and CEO of AAPM-American Association for Precision Medicine (http://www.aapm.health/) and is leading research efforts focused on preventing & curing chronic diseases; not only treating the sick but also providing knowledge/tools to individuals to live longer, healthier lives.
Widely recognized as a thought leader in the field of Technology and Healthcare, Dr. Mishra has keynoted, curated, chaired and organized numerous successful international conferences. Notably, he has served as an organizer and program chair for DANS: DataAI National Summit (http://www.dans.ai/), AAPM-ExPO: https://bit.ly/2mDpUyR (Excellence in Precision Oncology Summit), Breakthroughs in Precision Medicine Summit (https://bit.ly/335Tpcy), as well as AAPM Annual Meeting (https://www.a2pm.org/). ‘Knowledge saves lives’, has been his personal motto.
Prior to Agility Pharma, Dr. Mishra served as a Scientist and Principal Investigator at the pharma giant Genentech, Roche. Where he participated in several drug discovery project teams. He also lead the efforts to establish robotic automation (robotization) driven mammalian cell based phenotypic screening capabilities and hit to lead identification efforts within Genentech. Moreover, his passion for drug development and precision medicine has led to identification of new drug targets, biomarkers, companion diagnostics and several drugs/ combinations in the clinic.
His research work has been recognized globally by over 40 prestigious awards and honors. Due to his unique perspective & selfless service, he is highly respected & sought-after mentor to many. The companies that he has advised have raised multimillion dollars. Notably, he serves as a mentor and advisor to startup accelerators such as IndieBio, CLSA/Accenture’s Digital Health Initiative, HIMSS: Health2.0’s Project Zygote (digital health accelerator) and California Life Sciences Institute’s FAST program, to help grow California’s life sciences innovation ecosystem.

Prasun Mishra, PhDFounder, CEO, AAPM, Founder, Agility Pharma & MetaImmune Inc.

Dr. Mishra (Ex-Genentech, Ex-NCI, Ex-NIH) is the Founder and CEO of Agility Pharmaceuticals, a pharmaceutical company committed to revolutionizing drug discovery & development through technology, big data, robotics, and artificial intelligence. He is a serial entrepreneur who founded his first company after graduating high school, and second company during his PhD. Since then, he has accumulated a wealth of experienced by building, investing and advising numerous other companies. He is an investor/co-founder/board member of a few US based corporations focused on accelerating drug discovery & development, blockchain and digital health. Dr. Mishra is also founding president and CEO of AAPM-American Association for Precision Medicine (http://www.aapm.health/) and is leading research efforts focused on preventing & curing chronic diseases; not only treating the sick but also providing knowledge/tools to individuals to live longer, healthier lives.
Widely recognized as a thought leader in the field of Technology and Healthcare, Dr. Mishra has keynoted, curated, chaired and organized numerous successful international conferences. Notably, he has served as an organizer and program chair for DANS: DataAI National Summit (http://www.dans.ai/), AAPM-ExPO: https://bit.ly/2mDpUyR (Excellence in Precision Oncology Summit), Breakthroughs in Precision Medicine Summit (https://bit.ly/335Tpcy), as well as AAPM Annual Meeting (https://www.a2pm.org/). ‘Knowledge saves lives’, has been his personal motto.
Prior to Agility Pharma, Dr. Mishra served as a Scientist and Principal Investigator at the pharma giant Genentech, Roche. Where he participated in several drug discovery project teams. He also lead the efforts to establish robotic automation (robotization) driven mammalian cell based phenotypic screening capabilities and hit to lead identification efforts within Genentech. Moreover, his passion for drug development and precision medicine has led to identification of new drug targets, biomarkers, companion diagnostics and several drugs/ combinations in the clinic.
His research work has been recognized globally by over 40 prestigious awards and honors. Due to his unique perspective & selfless service, he is highly respected & sought-after mentor to many. The companies that he has advised have raised multimillion dollars. Notably, he serves as a mentor and advisor to startup accelerators such as IndieBio, CLSA/Accenture’s Digital Health Initiative, HIMSS: Health2.0’s Project Zygote (digital health accelerator) and California Life Sciences Institute’s FAST program, to help grow California’s life sciences innovation ecosystem.

closepopup
Sangeeta Marwaha, MDChair, Dermatology Technology Leads, Kaiser Permanente

Sangeeta Marwaha, MD is Chair of the Dermatology Technology Leads at Kaiser Permanente. She is a Medical and Surgical Dermatologist who is also a part of regional dermatology leadership team at Kaiser.
She is the Chief of Cosmetic Dermatology at Kaiser Permanente and an Clinical Instructor, UC Davis Dermatology Residency Program. She is also a part of Physician Wellness Program and Epic Dermatology Steering Committee.

Sangeeta Marwaha, MDChair, Dermatology Technology Leads, Kaiser Permanente

Sangeeta Marwaha, MD is Chair of the Dermatology Technology Leads at Kaiser Permanente. She is a Medical and Surgical Dermatologist who is also a part of regional dermatology leadership team at Kaiser.
She is the Chief of Cosmetic Dermatology at Kaiser Permanente and an Clinical Instructor, UC Davis Dermatology Residency Program. She is also a part of Physician Wellness Program and Epic Dermatology Steering Committee.

closepopup
Pier Federico Gherardini, PhDDirector, Informatics, Parker Institute for Cancer Immunotherapy

Pier Federico Gherardini, PhD, is director of informatics at PICI. His work focuses on the development of computational methods for the visualization and analysis of high-dimensional data, with a particular focus on single-cell analysis.

Gherardini has a strong passion for the development and application of new technologies and for thinking about the challenges such technologies bring to data analysis and interpretation. At PICI, his work focuses on the implementation of advanced assay technologies for the analysis of clinical samples, from evaluating new approaches to developing computational methods to visualize and analyze the resulting data. Gherardini is also interested in tools that support human-driven analysis of complex datasets, including interactive visualization methods and information systems that can support a rapid iteration cycle of analysis and interpretation.

Prior to joining PICI, Gherardini was a postdoctoral fellow in the lab of Garry P. Nolan, PhD, at Stanford, where he performed both computational and wet lab work. While at Stanford he developed a technology for highly multiplexed simultaneous measurement of proteins and RNAs in single cells by mass cytometry, as well as a method for building an interactive map of the immune system that incorporates prior knowledge about major cell types.

Gherardini holds master’s and doctoral degrees from the University of Rome Tor Vergata in Italy and a certificate from the Ignite program in innovation and entrepreneurship from the Stanford University Graduate School of Business.

Pier Federico Gherardini, PhDDirector, Informatics, Parker Institute for Cancer Immunotherapy

Pier Federico Gherardini, PhD, is director of informatics at PICI. His work focuses on the development of computational methods for the visualization and analysis of high-dimensional data, with a particular focus on single-cell analysis.

Gherardini has a strong passion for the development and application of new technologies and for thinking about the challenges such technologies bring to data analysis and interpretation. At PICI, his work focuses on the implementation of advanced assay technologies for the analysis of clinical samples, from evaluating new approaches to developing computational methods to visualize and analyze the resulting data. Gherardini is also interested in tools that support human-driven analysis of complex datasets, including interactive visualization methods and information systems that can support a rapid iteration cycle of analysis and interpretation.

Prior to joining PICI, Gherardini was a postdoctoral fellow in the lab of Garry P. Nolan, PhD, at Stanford, where he performed both computational and wet lab work. While at Stanford he developed a technology for highly multiplexed simultaneous measurement of proteins and RNAs in single cells by mass cytometry, as well as a method for building an interactive map of the immune system that incorporates prior knowledge about major cell types.

Gherardini holds master’s and doctoral degrees from the University of Rome Tor Vergata in Italy and a certificate from the Ignite program in innovation and entrepreneurship from the Stanford University Graduate School of Business.

closepopup
Robin FarmanfarmaianAuthor, Patient Advocate, Entrepreneur

Robin Farmanfarmaian is a professional speaker, entrepreneur, and angel investor working with cutting-edge Artificial Intelligence software, device and pharma companies poised to impact 100M patients.

With over 140 speaking engagements in 13 countries, she educates audiences on the future of healthcare, patient empowerment, building thought leadership, and many trends & technologies: Artificial intelligence, sensors, tissue engineering, nano, 3D printing, virtual healthcare, point of care diagnostics + medical device and more.

Robin has 2 published books: “The Patient as CEO: How Technology Empowers the Healthcare Consumer” and "The Thought Leader Formula: Strategically Leverage Your Expertise to Drive Business & Career Goals".

Robin FarmanfarmaianAuthor, Patient Advocate, Entrepreneur

Robin Farmanfarmaian is a professional speaker, entrepreneur, and angel investor working with cutting-edge Artificial Intelligence software, device and pharma companies poised to impact 100M patients.

With over 140 speaking engagements in 13 countries, she educates audiences on the future of healthcare, patient empowerment, building thought leadership, and many trends & technologies: Artificial intelligence, sensors, tissue engineering, nano, 3D printing, virtual healthcare, point of care diagnostics + medical device and more.

Robin has 2 published books: “The Patient as CEO: How Technology Empowers the Healthcare Consumer” and "The Thought Leader Formula: Strategically Leverage Your Expertise to Drive Business & Career Goals".

closepopup
Nishit Doshi, PhDDirector, Roche Molecular Systems

Nishit Doshi, PhD is a director at Roche Molecular Systems. He is an influential and innovative product leader who builds high-performance teams and heads product development strategy through delivery. He is known for motivating resources and aligning vision towards performance excellence. He has implemented processes that reaches beyond the traditional organizational structure to setup teams for success. He solves complex technical challenges through innovation and translates data into insights and actionable ideas for digital health and life sciences products, from concept through commercialization. He has experience in both startups and multi-national Fortune 500 healthcare firms from the technology and business perspective.

Nishit Doshi, PhDDirector, Roche Molecular Systems

Nishit Doshi, PhD is a director at Roche Molecular Systems. He is an influential and innovative product leader who builds high-performance teams and heads product development strategy through delivery. He is known for motivating resources and aligning vision towards performance excellence. He has implemented processes that reaches beyond the traditional organizational structure to setup teams for success. He solves complex technical challenges through innovation and translates data into insights and actionable ideas for digital health and life sciences products, from concept through commercialization. He has experience in both startups and multi-national Fortune 500 healthcare firms from the technology and business perspective.

closepopup
Elizabeth Baca, MD, MPASpecialist Leader at Deloitte, Former Deputy Director, Governor's Office of Planning and Research

Elizabeth Baca, MD is a specialist leader at Deloitte. She has served as the deputy director of the Governor's Office of Planning and Research (OPR), where she provided vision, leadership and oversight for the California Initiative to Advance Precision Medicine (CIAPM). Previously, Dr. Baca served on the General Pediatric Faculty at Stanford Medical School and directed the Community Pediatric and Child Advocacy Rotation. In addition to teaching medical students and residents about the social, economic, and environmental factors that affect health, Dr. Baca was the lead faculty mentor on several projects to increase access to healthy foods, reduce environmental triggers of asthma, increase physical activity opportunities, and improve the built environment.

Dr. Baca studied health policy at Universidad Simon Bolivar in Venezuela. She completed her Masters in Public Administration at Harvard Kennedy School of Government and her medical degree at Harvard Medical School. Dr. Baca completed her pediatric residency in the Pediatric Leadership for the Underserved (PLUS) program at UC San Francisco.

Elizabeth Baca, MD, MPASpecialist Leader at Deloitte, Former Deputy Director, Governor's Office of Planning and Research

Elizabeth Baca, MD is a specialist leader at Deloitte. She has served as the deputy director of the Governor's Office of Planning and Research (OPR), where she provided vision, leadership and oversight for the California Initiative to Advance Precision Medicine (CIAPM). Previously, Dr. Baca served on the General Pediatric Faculty at Stanford Medical School and directed the Community Pediatric and Child Advocacy Rotation. In addition to teaching medical students and residents about the social, economic, and environmental factors that affect health, Dr. Baca was the lead faculty mentor on several projects to increase access to healthy foods, reduce environmental triggers of asthma, increase physical activity opportunities, and improve the built environment.

Dr. Baca studied health policy at Universidad Simon Bolivar in Venezuela. She completed her Masters in Public Administration at Harvard Kennedy School of Government and her medical degree at Harvard Medical School. Dr. Baca completed her pediatric residency in the Pediatric Leadership for the Underserved (PLUS) program at UC San Francisco.

closepopup
Kimon Angelides, PhD, MBAFounder and CEO, Vivante Health

Kim is the founder of four healthcare companies: Vivante, Livongo, the leading digital diabetes company, DiabetesAmerica, a network of diabetes centers that pioneered the at-risk and bundled payment models, and mAbGen, a cancer biotech company that partnered with MDAnderson Cancer Center and was acquired by Valeant Pharmaceuticals.

Kim’s newest company, Vivante Health, was created in early 2016, after he left Livongo, to tackle the needs of people who have invisible and stigmatized diseases, who have been neglected in the healthcare system. The first product, GIThrive, takes on digestive diseases which affects more than 70M Americans. Digestive trouble is something most people don’t want to discuss. It’s understandable—symptoms like diarrhea, constipation, gas and bloating are embarrassing and stigmatized and drastically impact people’s home and work lives. His goal is to destigmatize these conditions by using state of the art psychosocial, clinical, nutritional and microbiome science to improve the lives of these people and to reduce healthcare costs.

Prior to his healthcare career, Kim was the Chief Strategic Officer at Tanox, Inc which sold to Genentech (NYSE: DNA) for $1B, Director of Strategic Development at St Luke’s/Texas Heart Institute, Professor and Chair of Cell Biology and Biomedical Sciences at the University of Durham in the UK, Professor of Cell Biology, Neuroscience, Biochemistry, and Molecular Biophysics at Baylor College of Medicine, and Associate and Assistant Professor at the University of Florida and McGill University. Kim has served on the National Medical Advisory Boards of the National Multiple Sclerosis Society, Muscular Dystrophy Association, and the National Institutes of Health. Kim was Research Career Development Award from the NIH, a Mombusho Scholar of Japan, Distinguished Professor at INSERM/Centre National de Recherche Scientifique of France, and a Basil O’Connor Scholar from the March of Dimes Birth Defect Foundation. He has published over 100 papers and holds more than 40 patents. He received a PhD in Chemistry from the University of California and has done graduate study in business, laws, and public health.

Kimon Angelides, PhD, MBAFounder and CEO, Vivante Health

Kim is the founder of four healthcare companies: Vivante, Livongo, the leading digital diabetes company, DiabetesAmerica, a network of diabetes centers that pioneered the at-risk and bundled payment models, and mAbGen, a cancer biotech company that partnered with MDAnderson Cancer Center and was acquired by Valeant Pharmaceuticals.

Kim’s newest company, Vivante Health, was created in early 2016, after he left Livongo, to tackle the needs of people who have invisible and stigmatized diseases, who have been neglected in the healthcare system. The first product, GIThrive, takes on digestive diseases which affects more than 70M Americans. Digestive trouble is something most people don’t want to discuss. It’s understandable—symptoms like diarrhea, constipation, gas and bloating are embarrassing and stigmatized and drastically impact people’s home and work lives. His goal is to destigmatize these conditions by using state of the art psychosocial, clinical, nutritional and microbiome science to improve the lives of these people and to reduce healthcare costs.

Prior to his healthcare career, Kim was the Chief Strategic Officer at Tanox, Inc which sold to Genentech (NYSE: DNA) for $1B, Director of Strategic Development at St Luke’s/Texas Heart Institute, Professor and Chair of Cell Biology and Biomedical Sciences at the University of Durham in the UK, Professor of Cell Biology, Neuroscience, Biochemistry, and Molecular Biophysics at Baylor College of Medicine, and Associate and Assistant Professor at the University of Florida and McGill University. Kim has served on the National Medical Advisory Boards of the National Multiple Sclerosis Society, Muscular Dystrophy Association, and the National Institutes of Health. Kim was Research Career Development Award from the NIH, a Mombusho Scholar of Japan, Distinguished Professor at INSERM/Centre National de Recherche Scientifique of France, and a Basil O’Connor Scholar from the March of Dimes Birth Defect Foundation. He has published over 100 papers and holds more than 40 patents. He received a PhD in Chemistry from the University of California and has done graduate study in business, laws, and public health.

closepopup
Julianne McCall, PhDScience Officer, CIAPM, The California Governor’s Office of Planning & Research

Julianne McCall holds a PhD in Neuroscience with sixteen years of laboratory experience, including at the Salk Institute, National Center for Microscopy Imaging Research, and Stanford University. A career pivot toward science policy led her to the California Legislature, where she worked for two years in the Senate Office of Research, including one year as a Science and Technology Policy Fellow. In that capacity, she covered several policy areas, including scientific research administration, public health, and developmental disabilities.

Throughout her career, Julianne established four public science education programs and directed the International “Brain Bee” Neuroscience Olympiad, a competition that engages over 50 countries. She was named International Student of the Year of Heidelberg University in 2011 and completed a Howard Hughes Medical Institute Med-Into-Grad Fellowship in 2010. As a Fulbright alumnus to Sweden, Julianne remains involved in the global alumni network as Co-Founder of TEDxFulbright.

Julianne earned a PhD in Neuroscience from Heidelberg University in Germany and a Masters degree in Biomedical Sciences from UC San Diego after graduating magna cum laude with a Bachelors degree in Neuroscience from Denison University.

Julianne McCall, PhDScience Officer, CIAPM, The California Governor’s Office of Planning & Research

Julianne McCall holds a PhD in Neuroscience with sixteen years of laboratory experience, including at the Salk Institute, National Center for Microscopy Imaging Research, and Stanford University. A career pivot toward science policy led her to the California Legislature, where she worked for two years in the Senate Office of Research, including one year as a Science and Technology Policy Fellow. In that capacity, she covered several policy areas, including scientific research administration, public health, and developmental disabilities.

Throughout her career, Julianne established four public science education programs and directed the International “Brain Bee” Neuroscience Olympiad, a competition that engages over 50 countries. She was named International Student of the Year of Heidelberg University in 2011 and completed a Howard Hughes Medical Institute Med-Into-Grad Fellowship in 2010. As a Fulbright alumnus to Sweden, Julianne remains involved in the global alumni network as Co-Founder of TEDxFulbright.

Julianne earned a PhD in Neuroscience from Heidelberg University in Germany and a Masters degree in Biomedical Sciences from UC San Diego after graduating magna cum laude with a Bachelors degree in Neuroscience from Denison University.

closepopup
Lynda Chin, MDFounder, CEO, Apricity Health LLC, Adjunct Professor of Oncology, Dell Medical School

Dr. Chin is an elected member of the National Academy of Medicine, a renowned cancer genomic scientist and a leader in application of technologies, AI/ML and big data in medicine. A dermatologist by training, Dr. Chin conducted research in cancer genomics and cancer biology at Dana Farber Cancer Institute and Harvard Medical School, served on the executive subcommittee of The Cancer Genome Atlas (TCGA) and co-led development of the Firehose pipeline at the Broad Institute. As the founding chair of Department of Genomic Medicine at MD Anderson, Dr. Chin developed cross-cutting capabilities with technologies, data and analytics, including the APOLLO platform to systematize workflows for patient-oriented research, the Translational Research Accelerator (TRA) to integrate longitudinal clinical and research data to democratize evidence-based care. Later, as Chief Innovation Officer of the University of Texas System, Dr. Chin launched Project DOC to incorporate digital technologies in chronic disease management for the underserved. She conceptualized and demonstrated feasibility of REDI (Real-world Education, early Detection and Intervention), a framework to orchestrate technology-enabled care in a digitally connected ecosystem. Presently, Dr. Chin is president and CEO of Apricity Health, a next-generation precision oncology company she co-founded to harness real-world patient data and world-class clinical expertise at points of care to improve therapy effectiveness, accelerate research and develop next-generation precision medicine.

Lynda Chin, MDFounder, CEO, Apricity Health LLC, Adjunct Professor of Oncology, Dell Medical School

Dr. Chin is an elected member of the National Academy of Medicine, a renowned cancer genomic scientist and a leader in application of technologies, AI/ML and big data in medicine. A dermatologist by training, Dr. Chin conducted research in cancer genomics and cancer biology at Dana Farber Cancer Institute and Harvard Medical School, served on the executive subcommittee of The Cancer Genome Atlas (TCGA) and co-led development of the Firehose pipeline at the Broad Institute. As the founding chair of Department of Genomic Medicine at MD Anderson, Dr. Chin developed cross-cutting capabilities with technologies, data and analytics, including the APOLLO platform to systematize workflows for patient-oriented research, the Translational Research Accelerator (TRA) to integrate longitudinal clinical and research data to democratize evidence-based care. Later, as Chief Innovation Officer of the University of Texas System, Dr. Chin launched Project DOC to incorporate digital technologies in chronic disease management for the underserved. She conceptualized and demonstrated feasibility of REDI (Real-world Education, early Detection and Intervention), a framework to orchestrate technology-enabled care in a digitally connected ecosystem. Presently, Dr. Chin is president and CEO of Apricity Health, a next-generation precision oncology company she co-founded to harness real-world patient data and world-class clinical expertise at points of care to improve therapy effectiveness, accelerate research and develop next-generation precision medicine.

closepopup
Ysabel DuronFounder, Director, Latino Cancer Institute

Ysabel Duron is Founder and Executive Director of Latinas Contra Cancer. A cancer survivor herself, she founded Latinas Contra Cancer, in 2003 to address the void in services for Latinos around issues of cancer including support services and education, particularly in the low-income, Spanish-speaking community. Duron, a television journalist for over 39 years, was inducted into the National Association of Hispanic Journalists Hall of Fame in 2009. The San Jose Silicon Valley Business Journal named her a Women of Influence in 2008. She was named one of the most Influential Bay Area Latinos in 2005 by the San Francisco Hispanic Chamber. In 2003, she won the Janet Gray Hayes Award for her meritorious work as a journalist and as an advocate for Latinas with breast cancer. Duron was awarded The Purpose Prize in 2013 by Encore.org.

Ysabel DuronFounder, Director, Latino Cancer Institute

Ysabel Duron is Founder and Executive Director of Latinas Contra Cancer. A cancer survivor herself, she founded Latinas Contra Cancer, in 2003 to address the void in services for Latinos around issues of cancer including support services and education, particularly in the low-income, Spanish-speaking community. Duron, a television journalist for over 39 years, was inducted into the National Association of Hispanic Journalists Hall of Fame in 2009. The San Jose Silicon Valley Business Journal named her a Women of Influence in 2008. She was named one of the most Influential Bay Area Latinos in 2005 by the San Francisco Hispanic Chamber. In 2003, she won the Janet Gray Hayes Award for her meritorious work as a journalist and as an advocate for Latinas with breast cancer. Duron was awarded The Purpose Prize in 2013 by Encore.org.

closepopup
John Mattison, MDChief Medical Information Officer, Assistant Medical Director, Emeritus, Kaiser Permanente

John Mattison, MD is the Chief Medical Information Officer, Assistant Medical Director, Emeritus, Kaiser Permanente. He focuses on transforming care delivery with information technology, through convergence of exponential technologies and data liquidity. He led the design and implementation of the largest integrated electronic health record in the US, and leads various national programs including virtual care. He has sponsored or led numerous digital innovations, and mentors many digital health startups. He chairs the eHealth Workgroup of the Global Alliance for Genomics and Health (GA4GH), and is a board member of Open mHealth, advisory board member of the NIH funded Policy and Ethics in Precision Medicine, teaches at multiple Universities including Singularity University, and has published widely on privacy, policy, security, IOT, global genomics collaboration, interoperability, mobile health, and healthcare transformation. He has published in Nature, JAMIA, JAMA, WSJ, Forbes, and has authored chapters for various books. He has keynoted or hosted many national and international healthcare conferences and has consulted in many countries. He is the founder of the international XML standard for health record interoperability known as CDA, CCD and CCDA, and is an active participant on several global initiatives to bring internet services to underserved communities providing access to both jobs and healthcare. Full bio available upon request.

John Mattison, MDChief Medical Information Officer, Assistant Medical Director, Emeritus, Kaiser Permanente

John Mattison, MD is the Chief Medical Information Officer, Assistant Medical Director, Emeritus, Kaiser Permanente. He focuses on transforming care delivery with information technology, through convergence of exponential technologies and data liquidity. He led the design and implementation of the largest integrated electronic health record in the US, and leads various national programs including virtual care. He has sponsored or led numerous digital innovations, and mentors many digital health startups. He chairs the eHealth Workgroup of the Global Alliance for Genomics and Health (GA4GH), and is a board member of Open mHealth, advisory board member of the NIH funded Policy and Ethics in Precision Medicine, teaches at multiple Universities including Singularity University, and has published widely on privacy, policy, security, IOT, global genomics collaboration, interoperability, mobile health, and healthcare transformation. He has published in Nature, JAMIA, JAMA, WSJ, Forbes, and has authored chapters for various books. He has keynoted or hosted many national and international healthcare conferences and has consulted in many countries. He is the founder of the international XML standard for health record interoperability known as CDA, CCD and CCDA, and is an active participant on several global initiatives to bring internet services to underserved communities providing access to both jobs and healthcare. Full bio available upon request.

closepopup
Felix Matthews, MD, MBAManaging Director, Deloitte

Felix is a managing director and physician leader at Deloitte Consulting LLP. He advises his clients on strategies to succeed in an increasingly competitive market. His clients include academic health centers, national health systems, health plans, and life sciences companies. He is experienced in corporate strategy, pre-deal strategic fit assessments, clinical affiliation strategy, care model innovation, value-based payments, operating model, physician engagement, and digital strategy, among others. He also advises his clients on strategy implementation and enabling capabilities.

With more than 15 years combined experience in medical practice and health care consulting, Felix brings to his clients a unique blend of clinical understanding and business insight. Felix trained in trauma surgery and accident medicine and has led research focused on clinical technology innovation at major academic centers in the United States and abroad. Felix is also a published author in peer-reviewed medical journals.

Felix Matthews, MD, MBAManaging Director, Deloitte

Felix is a managing director and physician leader at Deloitte Consulting LLP. He advises his clients on strategies to succeed in an increasingly competitive market. His clients include academic health centers, national health systems, health plans, and life sciences companies. He is experienced in corporate strategy, pre-deal strategic fit assessments, clinical affiliation strategy, care model innovation, value-based payments, operating model, physician engagement, and digital strategy, among others. He also advises his clients on strategy implementation and enabling capabilities.

With more than 15 years combined experience in medical practice and health care consulting, Felix brings to his clients a unique blend of clinical understanding and business insight. Felix trained in trauma surgery and accident medicine and has led research focused on clinical technology innovation at major academic centers in the United States and abroad. Felix is also a published author in peer-reviewed medical journals.

closepopup
Shyamali Singhal, MDDirector of Cancer Center, El Camino Hospital

Shyamali Singhal MD, is an accomplished Senior Executive and Thought Leader with more than 22 years of success across the healthcare industry. Leveraging extensive experience leading operations, clinical trials, quality control, and feedback, she is a valuable advisor for an organization implementing market strategies or positioning for growth. Her broad areas of expertise include oncology, medical devices, business strategy, business planning, and organizational leadership.

Throughout her executive career, Shyamali has held leadership positions with El Camino Hospital and Hope and Beauty.

Shyamali Singhal, MDDirector of Cancer Center, El Camino Hospital

Shyamali Singhal MD, is an accomplished Senior Executive and Thought Leader with more than 22 years of success across the healthcare industry. Leveraging extensive experience leading operations, clinical trials, quality control, and feedback, she is a valuable advisor for an organization implementing market strategies or positioning for growth. Her broad areas of expertise include oncology, medical devices, business strategy, business planning, and organizational leadership.

Throughout her executive career, Shyamali has held leadership positions with El Camino Hospital and Hope and Beauty.

closepopup
Shannon Muir, PhDScience Officer, CIAPM, The California Governor’s Office of Planning & Research

Dr. Muir co-leads the California Initiative to Advance Precision Medicine. In this role, she works with the Precision Medicine Advisory Council and the Governor’s Office in the selection and management of grants for precision medicine demonstration projects. Her current portfolio consists of projects that aim to address health disparities in cancer prevention and treatment. Dr. Muir also manages strategic relationships with State entities and other stakeholders including community groups, academics, and private sector partners. She previously served as a Director of the Research Proposal Development Service at UC San Diego, as well as a Senior Program Associate and Science and Technology Policy Fellow in the Senate Health Committee for the California Council on Science and Technology. Dr. Muir received a PhD in Biomedical Sciences from UC San Diego, an MS in Pharmacology from Tulane University, and BS in Psychobiology from UCLA.

Shannon Muir, PhDScience Officer, CIAPM, The California Governor’s Office of Planning & Research

Dr. Muir co-leads the California Initiative to Advance Precision Medicine. In this role, she works with the Precision Medicine Advisory Council and the Governor’s Office in the selection and management of grants for precision medicine demonstration projects. Her current portfolio consists of projects that aim to address health disparities in cancer prevention and treatment. Dr. Muir also manages strategic relationships with State entities and other stakeholders including community groups, academics, and private sector partners. She previously served as a Director of the Research Proposal Development Service at UC San Diego, as well as a Senior Program Associate and Science and Technology Policy Fellow in the Senate Health Committee for the California Council on Science and Technology. Dr. Muir received a PhD in Biomedical Sciences from UC San Diego, an MS in Pharmacology from Tulane University, and BS in Psychobiology from UCLA.

closepopup
Hiroomi Tada MD PhDChief Medical Officer at Notable Labs

Hiroomi Tada, MD, PhD, oversees Notable’s clinical operations and brings decades of experience in cancer drug development to Notable. Surgical Oncologist and pharma veteran turned CMO, Tada is a specialist in translational science and clinical drug development, was most recently VP Targeted Therapies, Translational Sciences at Incyte Corporation, where he lead investigations of Incyte’s large targeted therapy portfolio in oncology. Prior to that, he was Medical Director, Oncology Clinical Development at GlaxoSmithKline and Director, Clinical Research at AstraZeneca. Tada is an M.D. who also has a PhD in Molecular Biology.

Hiroomi Tada MD PhDChief Medical Officer at Notable Labs

Hiroomi Tada, MD, PhD, oversees Notable’s clinical operations and brings decades of experience in cancer drug development to Notable. Surgical Oncologist and pharma veteran turned CMO, Tada is a specialist in translational science and clinical drug development, was most recently VP Targeted Therapies, Translational Sciences at Incyte Corporation, where he lead investigations of Incyte’s large targeted therapy portfolio in oncology. Prior to that, he was Medical Director, Oncology Clinical Development at GlaxoSmithKline and Director, Clinical Research at AstraZeneca. Tada is an M.D. who also has a PhD in Molecular Biology.

closepopup
Michael Gillam, MDFounder, CEO, HealthLab, Former Director, Microsoft Healthcare Innovation Lab

Michael Gillam, MD, FACEP, is CEO of HealthLab, a discovery automation company for “big data” and machine intelligence models. He has helped build and sell companies to WebMD and Microsoft and built a direct-to-consumer digital athletics company whose mobile app was called “game changing” by Apple and put in a commercial. He has served as a partner level executive in Microsoft and advised companies, health ministries and NGOs regarding their healthcare data strategies particularly in China and the Middle East. Dr. Gillam was research director for the big data aggregation solution, Azyxxi, which was acquired by Microsoft in 2006 to become one of their flagship products for healthcare, renamed Amalga He is a board certified emergency medicine physician who trained, practiced, and taught at Northwestern University in Chicago. He written over fifty papers and abstracts and has eleven patents in healthcare technology. He has served as Chair of Informatics for both the Society for Academic Emergency Medicine and the American College of Emergency Physicians. Dr. Gillam is a judge on the IBM AI XPrize, was the chief clinical judge for the Qualcomm Tricorder XPrize, and also served as a judge on the Nokia Sensing XPrize. Dr. Gillam founded and ran healthcare innovation labs for almost 10 years in Microsoft and in Washington D.C. and led projects spanning: predictive analytics; anomalous event detection; natural language processing (NLP); gesture based interfaces; de-identification; personal health records (PHRs); virtual & augmented reality; and medical robotics.

Michael Gillam, MDFounder, CEO, HealthLab, Former Director, Microsoft Healthcare Innovation Lab

Michael Gillam, MD, FACEP, is CEO of HealthLab, a discovery automation company for “big data” and machine intelligence models. He has helped build and sell companies to WebMD and Microsoft and built a direct-to-consumer digital athletics company whose mobile app was called “game changing” by Apple and put in a commercial. He has served as a partner level executive in Microsoft and advised companies, health ministries and NGOs regarding their healthcare data strategies particularly in China and the Middle East. Dr. Gillam was research director for the big data aggregation solution, Azyxxi, which was acquired by Microsoft in 2006 to become one of their flagship products for healthcare, renamed Amalga He is a board certified emergency medicine physician who trained, practiced, and taught at Northwestern University in Chicago. He written over fifty papers and abstracts and has eleven patents in healthcare technology. He has served as Chair of Informatics for both the Society for Academic Emergency Medicine and the American College of Emergency Physicians. Dr. Gillam is a judge on the IBM AI XPrize, was the chief clinical judge for the Qualcomm Tricorder XPrize, and also served as a judge on the Nokia Sensing XPrize. Dr. Gillam founded and ran healthcare innovation labs for almost 10 years in Microsoft and in Washington D.C. and led projects spanning: predictive analytics; anomalous event detection; natural language processing (NLP); gesture based interfaces; de-identification; personal health records (PHRs); virtual & augmented reality; and medical robotics.

closepopup
Mirella Lazarov, DDS, PhDHead of the Companion Diagnostics Center of Excellence (CDx COE) at AbbVie

Biomarkers and translational medicine leader with over 18 years of experience specializing in the areas of oncology, immunology and inflammation, ophthalmology, IBD, respiratory diseases, renal disease, and fibrosis. Strong background in the biotech and global pharmaceutical drug development process from target assessment through clinical development and approval. Expertise in managing products through various research and development stages, from inception through clinical trials. Proven ability to build, develop and manage cross-functional research, clinical development, biomarker and diagnostics teams in a matrix driven environment. Strong people management experience directing both small and large departments.

- Strong expertise in developing and implementing biomarker and companion diagnostics strategies from drug discovery through post-marketing activities across multiple therapeutic areas including oncology, immunology & inflammation, ophthalmology, fibrosis, virology, respiratory, and cardiovascular diseases.
- Successfully co-developed therapeutics with companion diagnostics, including Tarceva (erlotinib) for 1L NSCLC, Zelboraf (vemurafenib), and Onartuzumab (MetMab).
- Experienced in the discovery, development, validation and appropriate clinical utilization of biomarker assays, including pharmacodynamic, mechanism of action, safety, predictive, prognostic and monitoring biomarkers to be used as surrogate endpoints and/or as companion diagnostics.
- Strong scientific background in signal transduction, cellular pharmacology and molecular biology with peer reviewed scientific publications in Nature and Nature Medicine.
- Successfully built from the ground up and directed Preclinical Development, Development Sciences, Biomarker and Companion Diagnostics Departments in both start-up and mid-size Biotechnology companies

Job Related Accomplishements

- AbbVie: Established and leads the Companion Diagnostics Center of Excellence at Abbvie

Mirella Lazarov, DDS, PhDHead of the Companion Diagnostics Center of Excellence (CDx COE) at AbbVie

Biomarkers and translational medicine leader with over 18 years of experience specializing in the areas of oncology, immunology and inflammation, ophthalmology, IBD, respiratory diseases, renal disease, and fibrosis. Strong background in the biotech and global pharmaceutical drug development process from target assessment through clinical development and approval. Expertise in managing products through various research and development stages, from inception through clinical trials. Proven ability to build, develop and manage cross-functional research, clinical development, biomarker and diagnostics teams in a matrix driven environment. Strong people management experience directing both small and large departments.

- Strong expertise in developing and implementing biomarker and companion diagnostics strategies from drug discovery through post-marketing activities across multiple therapeutic areas including oncology, immunology & inflammation, ophthalmology, fibrosis, virology, respiratory, and cardiovascular diseases.
- Successfully co-developed therapeutics with companion diagnostics, including Tarceva (erlotinib) for 1L NSCLC, Zelboraf (vemurafenib), and Onartuzumab (MetMab).
- Experienced in the discovery, development, validation and appropriate clinical utilization of biomarker assays, including pharmacodynamic, mechanism of action, safety, predictive, prognostic and monitoring biomarkers to be used as surrogate endpoints and/or as companion diagnostics.
- Strong scientific background in signal transduction, cellular pharmacology and molecular biology with peer reviewed scientific publications in Nature and Nature Medicine.
- Successfully built from the ground up and directed Preclinical Development, Development Sciences, Biomarker and Companion Diagnostics Departments in both start-up and mid-size Biotechnology companies

Job Related Accomplishements

- AbbVie: Established and leads the Companion Diagnostics Center of Excellence at Abbvie

closepopup
Andrew Chacko, MD, MSEFounder & Principal at ChackoMD

Dr. J. Andrew Chacko is a leader in Healthcare Innovation. He is a highly sought after public-speaker and consultant on a broad array of topics from Design Thinking, Leadership, Healthcare, Education, Digital Health, Mental Health and Wellness. As the only practicing clinician to have graduated from the Stanford program that pioneered Design Thinking, he seamlessly knits together years of expertise in three seemingly disparate cultures.

He built his deep understanding of Healthcare through clinical experience as a psychiatrist, attending physician, medical director and clinic director. He became an expert in Design Thinking and Innovation, studying at its pioneering institution, the Product Design graduate program at Stanford, then working at IDEO and finally teaching these principles around the world, starting at Stanford. His hard-won acumen as a leader and team-builder began long before his admittance to the U.S. Naval Academy, and continued through his career as a Naval Officer and beyond. His singular mission is to help institutions and people transform the future of healthcare.
J. Andrew Chacko.USN.jpg

His unique perspective allows him to conceptualize the problems facing the healthcare industry from multiple angles. He passionately shares that ability with others through his advising and consultation work, and happily cultivates that awareness in clinicians, engineers, designers and entrepreneurs through his courses and lectures on how to implement Design Thinking and Leadership in Healthcare.

He is the founder of ChackoMD, a company he formed to drive Healthcare Innovation. As its principal, he has taught at universities, conferences and institutions around the world, from Stanford University, UC Berkeley, Tokyo University, for the American Psychiatric Association, the American Medical Association, to pharmaceutical companies, associations of medical education professionals and Google. He has also advised multiple healthcare institutions, numerous healthcare technology start-ups, including Pear Therapeutics, and design consultancies, and was faculty at NODE: Digital Health University, and Project Zygote, a Health 2.0 accelerator.

He is a Board-Certified Psychiatrist, now running a private clinic in San Francisco, recently having most recently worked for the VA, UCSF and Stanford, as a Medical Director and an attending Psychiatrist. He completed his training at Tripler Army Medical Center, where he was honored as the only civilian selected for a military psychiatry residency, gaining special expertise in PTSD and Traumatic Brain Injury.

He earned his MD from Tufts University School of Medicine. He is a graduate of the U. S. Naval Academy, and served 12 years in the Navy, before completing his post-baccalaureate studies through Harvard. He earned his graduate degree at Stanford, studying both Mechanical Engineering and Art in the Joint Program in Design, taking an extra year for an in depth focus on Robotics, working as a designer independently and at IDEO.

He is an accomplished artist in wood-working, painting, and graphic design, and enjoys making just about anything from robots to furniture. His work has been galleried and sold. He loves dancing, has won dance competitions and is a certified Zumba Instructor. He is a certified military parachutist and rescue diver. He loves travel and exploring other cultures, having studied French, Spanish and Japanese. His biggest passion, however, is teaching (which he has done in some form since high-school) and drawing out human potential. His audiences have called him inspiring to life-changing. One of his favorite compliments came from a security guard at a lecture on the difficulties of innovating in healthcare, who later said that he “loved it so much [he] took notes the whole time!”

Andrew Chacko, MD, MSEFounder & Principal at ChackoMD

Dr. J. Andrew Chacko is a leader in Healthcare Innovation. He is a highly sought after public-speaker and consultant on a broad array of topics from Design Thinking, Leadership, Healthcare, Education, Digital Health, Mental Health and Wellness. As the only practicing clinician to have graduated from the Stanford program that pioneered Design Thinking, he seamlessly knits together years of expertise in three seemingly disparate cultures.

He built his deep understanding of Healthcare through clinical experience as a psychiatrist, attending physician, medical director and clinic director. He became an expert in Design Thinking and Innovation, studying at its pioneering institution, the Product Design graduate program at Stanford, then working at IDEO and finally teaching these principles around the world, starting at Stanford. His hard-won acumen as a leader and team-builder began long before his admittance to the U.S. Naval Academy, and continued through his career as a Naval Officer and beyond. His singular mission is to help institutions and people transform the future of healthcare.
J. Andrew Chacko.USN.jpg

His unique perspective allows him to conceptualize the problems facing the healthcare industry from multiple angles. He passionately shares that ability with others through his advising and consultation work, and happily cultivates that awareness in clinicians, engineers, designers and entrepreneurs through his courses and lectures on how to implement Design Thinking and Leadership in Healthcare.

He is the founder of ChackoMD, a company he formed to drive Healthcare Innovation. As its principal, he has taught at universities, conferences and institutions around the world, from Stanford University, UC Berkeley, Tokyo University, for the American Psychiatric Association, the American Medical Association, to pharmaceutical companies, associations of medical education professionals and Google. He has also advised multiple healthcare institutions, numerous healthcare technology start-ups, including Pear Therapeutics, and design consultancies, and was faculty at NODE: Digital Health University, and Project Zygote, a Health 2.0 accelerator.

He is a Board-Certified Psychiatrist, now running a private clinic in San Francisco, recently having most recently worked for the VA, UCSF and Stanford, as a Medical Director and an attending Psychiatrist. He completed his training at Tripler Army Medical Center, where he was honored as the only civilian selected for a military psychiatry residency, gaining special expertise in PTSD and Traumatic Brain Injury.

He earned his MD from Tufts University School of Medicine. He is a graduate of the U. S. Naval Academy, and served 12 years in the Navy, before completing his post-baccalaureate studies through Harvard. He earned his graduate degree at Stanford, studying both Mechanical Engineering and Art in the Joint Program in Design, taking an extra year for an in depth focus on Robotics, working as a designer independently and at IDEO.

He is an accomplished artist in wood-working, painting, and graphic design, and enjoys making just about anything from robots to furniture. His work has been galleried and sold. He loves dancing, has won dance competitions and is a certified Zumba Instructor. He is a certified military parachutist and rescue diver. He loves travel and exploring other cultures, having studied French, Spanish and Japanese. His biggest passion, however, is teaching (which he has done in some form since high-school) and drawing out human potential. His audiences have called him inspiring to life-changing. One of his favorite compliments came from a security guard at a lecture on the difficulties of innovating in healthcare, who later said that he “loved it so much [he] took notes the whole time!”

closepopup
Anupam Agarwal, MDVP, Harvard Club SF, VP, Zogenix Inc.

Anupam Agarwal MD is the Vice President and global head of safety & pharmacovigilance at Zogenix Inc. He is a cardiologist by training with over two decades of experience in treating patients and clinical research in academia. He is working in the pharmaceutical industry for more than 12 years. He was involved with research in the genetics of hypertension; drug eluted coronary stents at Brigham and Women’s Hospital, Harvard Medical School.
Anupam holds a medical degree from the GSVM Medical College, Kanpur, India and a Master of Public Health degree from the Harvard School of Public Health. He is a member of scientific oversight committee at the Cardiac Safety Research Consortium (CSRC) a think tank which was launched through an FDA Critical Path Initiative with Duke University to support research into the evaluation of cardiac safety of medical products.

Anupam Agarwal, MDVP, Harvard Club SF, VP, Zogenix Inc.

Anupam Agarwal MD is the Vice President and global head of safety & pharmacovigilance at Zogenix Inc. He is a cardiologist by training with over two decades of experience in treating patients and clinical research in academia. He is working in the pharmaceutical industry for more than 12 years. He was involved with research in the genetics of hypertension; drug eluted coronary stents at Brigham and Women’s Hospital, Harvard Medical School.
Anupam holds a medical degree from the GSVM Medical College, Kanpur, India and a Master of Public Health degree from the Harvard School of Public Health. He is a member of scientific oversight committee at the Cardiac Safety Research Consortium (CSRC) a think tank which was launched through an FDA Critical Path Initiative with Duke University to support research into the evaluation of cardiac safety of medical products.

closepopup
Uli K. Chettipally, MD.Founder InnovatorMD, Former Kaiser Permanente

Dr. Chettipally is a speaker, emergency physician, researcher, and an innovator, founder of InnovatorMD. He is passionate about the technology-enabled care that can decrease the burden on physicians and increase the value for patients. As the Co-founder and Chief Technology Officer of CREST Network, he designed, developed and implemented a clinical decision support platform to deliver real-time guidance at the point of care, to decrease the cognitive burden on physicians and improve patient outcomes in 21 hospitals. He received the "Pioneer Award" from Kaiser Permanente Innovations and "Morris F. Collen Research Award" from The Permanente Medical Group for his groundbreaking work. His other roles include President, Society of Physician Entrepreneurs, San Francisco Bay Area chapter; Assistant Clinical Professor of Medicine at the University of California, San Francisco; and is the Secretary/Treasurer, San Mateo County Medical Association.

Uli K. Chettipally, MD.Founder InnovatorMD, Former Kaiser Permanente

Dr. Chettipally is a speaker, emergency physician, researcher, and an innovator, founder of InnovatorMD. He is passionate about the technology-enabled care that can decrease the burden on physicians and increase the value for patients. As the Co-founder and Chief Technology Officer of CREST Network, he designed, developed and implemented a clinical decision support platform to deliver real-time guidance at the point of care, to decrease the cognitive burden on physicians and improve patient outcomes in 21 hospitals. He received the "Pioneer Award" from Kaiser Permanente Innovations and "Morris F. Collen Research Award" from The Permanente Medical Group for his groundbreaking work. His other roles include President, Society of Physician Entrepreneurs, San Francisco Bay Area chapter; Assistant Clinical Professor of Medicine at the University of California, San Francisco; and is the Secretary/Treasurer, San Mateo County Medical Association.

closepopup
Alan S. Young, MD, MBA, PMPChief Medical Officer, GYANT

Dr. Alan Young is a physician leader with strong clinical and business accomplishments. After completing a dual MD/MBA degree program at USC's Keck School of Medicine & Marshall School of Business, he obtained his medical license during his Orthopedic Surgery residency. Combining his passion for business & medicine, he served as a national healthcare subject matter expert Specialist Senior Consultant with Deloitte Consulting while providing surgical physician services at Southern California Kaiser Permanente. At USC Care Medical Group he was the Director of Operations Strategy and Special Projects, leading ambulatory quality improvement initiatives and electronic health record optimization efforts to improve both patient and physician engagement. He served as the Regional Director of Client Relations with Sagacious Consultants and Senior Manager with Accenture to drive business development for EPIC EMR solutions and recently was the Client Service Leader for Slalom Consulting in LA building their healthcare and life sciences portfolio while working with large health systems and insurance companies. Currently, he is the Chief Medical Officer for Gyant, an artificial intelligence powered software company working to engage patients and providers. He is a regular speaker and moderator for HIMSS, Health Care Executives and AI Med as well as a contributing author to a text book on Digital Health Entrepreneurship.
His clinical experience spans across Orthopedic/General Surgery, Emergency Medicine, Urgent Care, outpatient ambulatory clinics, specialty pediatric hospitals, HMO and VA hospitals. International health experience includes completion of a clinical elective program at the National Taiwan University School of Medicine in Orthopedics as well as two volunteer medical missions trips to Cambodia and Haiti. He currently practices medicine in the greater Los Angeles area and he also serves as the So Cal HIMSS CMIO Committee Chair, Society of Physician Entrepreneurs LA Chapter Leader, AIMed Ambassador and a ScaleLA Healthcare Committee member.

Alan S. Young, MD, MBA, PMPChief Medical Officer, GYANT

Dr. Alan Young is a physician leader with strong clinical and business accomplishments. After completing a dual MD/MBA degree program at USC's Keck School of Medicine & Marshall School of Business, he obtained his medical license during his Orthopedic Surgery residency. Combining his passion for business & medicine, he served as a national healthcare subject matter expert Specialist Senior Consultant with Deloitte Consulting while providing surgical physician services at Southern California Kaiser Permanente. At USC Care Medical Group he was the Director of Operations Strategy and Special Projects, leading ambulatory quality improvement initiatives and electronic health record optimization efforts to improve both patient and physician engagement. He served as the Regional Director of Client Relations with Sagacious Consultants and Senior Manager with Accenture to drive business development for EPIC EMR solutions and recently was the Client Service Leader for Slalom Consulting in LA building their healthcare and life sciences portfolio while working with large health systems and insurance companies. Currently, he is the Chief Medical Officer for Gyant, an artificial intelligence powered software company working to engage patients and providers. He is a regular speaker and moderator for HIMSS, Health Care Executives and AI Med as well as a contributing author to a text book on Digital Health Entrepreneurship.
His clinical experience spans across Orthopedic/General Surgery, Emergency Medicine, Urgent Care, outpatient ambulatory clinics, specialty pediatric hospitals, HMO and VA hospitals. International health experience includes completion of a clinical elective program at the National Taiwan University School of Medicine in Orthopedics as well as two volunteer medical missions trips to Cambodia and Haiti. He currently practices medicine in the greater Los Angeles area and he also serves as the So Cal HIMSS CMIO Committee Chair, Society of Physician Entrepreneurs LA Chapter Leader, AIMed Ambassador and a ScaleLA Healthcare Committee member.

closepopup
Pritmohinder Gill, PhDAssociate Professor, Arkansas Children’s Research Institute, UAMS

Pritmohinder Gill, PhD, received his PhD in Biological Anthropology from Southern Illinois University, Carbondale and has over 25 years of expertise studying human genetics. Dr. Gill joined ACRI in November 2012 and his research interests include the use of omic- technologies in discovering novel and sensitive biomarkers in human disease.

Under the direction of Dr. Schaefer, Dr. Gill will head the pediatric experimental therapeutics and precision medicine programs to aid in molecular profiling for patients with difficult conditions. The goal is to better target therapies for children with challenging diseases.

Dr. Gill is also interested in the role of miRNAs in the development of autism spectrum disorder (Dr. Shannon Rose) and acetaminophen drug toxicity (Dr. Laura James).

Dr. Gill’s work aims to advance the current knowledge of epigenetic involvement in diseases and understand interactions that influence genetic regulation. This will help the translation of basic discoveries to identify novel targets for drug development and better therapeutic intervention.

Pritmohinder Gill, PhDAssociate Professor, Arkansas Children’s Research Institute, UAMS

Pritmohinder Gill, PhD, received his PhD in Biological Anthropology from Southern Illinois University, Carbondale and has over 25 years of expertise studying human genetics. Dr. Gill joined ACRI in November 2012 and his research interests include the use of omic- technologies in discovering novel and sensitive biomarkers in human disease.

Under the direction of Dr. Schaefer, Dr. Gill will head the pediatric experimental therapeutics and precision medicine programs to aid in molecular profiling for patients with difficult conditions. The goal is to better target therapies for children with challenging diseases.

Dr. Gill is also interested in the role of miRNAs in the development of autism spectrum disorder (Dr. Shannon Rose) and acetaminophen drug toxicity (Dr. Laura James).

Dr. Gill’s work aims to advance the current knowledge of epigenetic involvement in diseases and understand interactions that influence genetic regulation. This will help the translation of basic discoveries to identify novel targets for drug development and better therapeutic intervention.

closepopup
Hunter Whitney,Consultant and Author (UX and Data Visualization)

Hunter Whitney is a consultant, author, and instructor who brings a distinct UX design perspective to data visualization. He has advised corporations, start-ups, government agencies, and NGOs to achieve their goals through a thoughtful, strategic design approach to digital products and services.

Hunter is the author of "Data Insights: New Ways to Visualize and Make Sense of Data”. He was also asked to contribute a chapter in the book, “Designing for Emerging Technologies: UX for Genomics, Robotics, and the Internet of Things”. Additionally, Hunter has written numerous articles covering a range of subjects for various online and print publications including UX Magazine.

Hunter Whitney,Consultant and Author (UX and Data Visualization)

Hunter Whitney is a consultant, author, and instructor who brings a distinct UX design perspective to data visualization. He has advised corporations, start-ups, government agencies, and NGOs to achieve their goals through a thoughtful, strategic design approach to digital products and services.

Hunter is the author of "Data Insights: New Ways to Visualize and Make Sense of Data”. He was also asked to contribute a chapter in the book, “Designing for Emerging Technologies: UX for Genomics, Robotics, and the Internet of Things”. Additionally, Hunter has written numerous articles covering a range of subjects for various online and print publications including UX Magazine.

closepopup
Kristine Mechem, PhDVP at Health Advances

Kristine has over 15 years of Life Science industry experience that spans diagnostics, medical devices, and therapeutics. She has held positions in market planning, business analytics, marketing, and business development.

Most recently, Kristine spent four years at a small cap oncology molecular diagnostic company where she led marketing and planning. During that time, she helped to take the company public, led the portfolio management and corporate planning efforts, and developed the commercial plan for their launch. She led the team that was responsible for the full range of commercial activities including: product development requirements, pricing strategy, market access strategy, salesforce sizing and customer service.

In addition to her oncology experience, Kristine has worked in metabolics, with positions at Genentech and Abbott, and in maternal health (early stage molecular diagnostic company). During her career she has been on five product launch teams with responsibilities for launch planning and KPI tracking.

Prior to her Life Science career, Kristine spent 15 years in commercial positions in high tech.

Kristine has a PhD from the University of Chicago and has completed the Executive Program in Strategy and Organization from the Stanford Graduate School of Business. She is also an active member of Women in Bio.

Kristine Mechem, PhDVP at Health Advances

Kristine has over 15 years of Life Science industry experience that spans diagnostics, medical devices, and therapeutics. She has held positions in market planning, business analytics, marketing, and business development.

Most recently, Kristine spent four years at a small cap oncology molecular diagnostic company where she led marketing and planning. During that time, she helped to take the company public, led the portfolio management and corporate planning efforts, and developed the commercial plan for their launch. She led the team that was responsible for the full range of commercial activities including: product development requirements, pricing strategy, market access strategy, salesforce sizing and customer service.

In addition to her oncology experience, Kristine has worked in metabolics, with positions at Genentech and Abbott, and in maternal health (early stage molecular diagnostic company). During her career she has been on five product launch teams with responsibilities for launch planning and KPI tracking.

Prior to her Life Science career, Kristine spent 15 years in commercial positions in high tech.

Kristine has a PhD from the University of Chicago and has completed the Executive Program in Strategy and Organization from the Stanford Graduate School of Business. She is also an active member of Women in Bio.

closepopup
Rajiv PratapChief Business Officer at Abzooba Inc.

Alumnus of the prestigious IBM T.J. Watson Research Lab, Rajiv has over 23 years of experience with creating disruptive value with data and analytics. His areas of expertise include AI, Deep Learning, Big Data, Predictive Analytics, innovative Big Data architecture, and deriving disruptive value from large amounts of structured and unstructured data. In his current role at Abzooba Inc, Rajiv is creating innovative technologies and products in conversational intelligence and bots with nuanced cognitive understanding of language (textual and speech), and vision. Rajiv owns Abzooba's flagship offering called xpresso.ai - a platform that provides cognitive bots that use Artificial Intelligence, Deep Learning, Natural Language Understanding, Computer Vision and other leading edge and technologies to empower consumers and enterprises cognitively.

His area of expertise encompasses innovative and ground-breaking work in the field of Artificial Intelligence, Deep Learning, Data mining and business intelligence architecture using latest technologies to deliver cognitive analytics, decision support tools and actionable knowledge to end-users over the Internet. Mr. Pratap has co-authored several pioneering technical papers/research reports for very prestigious publications and two international patents.

Rajiv was a founding member of Virtual Gold, Inc. (www.virtualgold.com) , a NY based data mining and BI company, and Avita Software Pvt. Ltd. He also served as the CTO of ChiMatrix, LLC (www.avitasoftware.com), a NY based company that focused on electronic data capture and advanced analytics for the pharmaceutical domain.

Rajiv has been educated at the Indian Institute of Technology, Kanpur, India (B. Tech., Computer Science, 1993).

Specialties: AI, Machine Learning, Deep Learning, Big Data, Knowledge discovery, data mining, advanced analytics, cognitive workflow automation for sales and marketing enablement.

Rajiv PratapChief Business Officer at Abzooba Inc.

Alumnus of the prestigious IBM T.J. Watson Research Lab, Rajiv has over 23 years of experience with creating disruptive value with data and analytics. His areas of expertise include AI, Deep Learning, Big Data, Predictive Analytics, innovative Big Data architecture, and deriving disruptive value from large amounts of structured and unstructured data. In his current role at Abzooba Inc, Rajiv is creating innovative technologies and products in conversational intelligence and bots with nuanced cognitive understanding of language (textual and speech), and vision. Rajiv owns Abzooba's flagship offering called xpresso.ai - a platform that provides cognitive bots that use Artificial Intelligence, Deep Learning, Natural Language Understanding, Computer Vision and other leading edge and technologies to empower consumers and enterprises cognitively.

His area of expertise encompasses innovative and ground-breaking work in the field of Artificial Intelligence, Deep Learning, Data mining and business intelligence architecture using latest technologies to deliver cognitive analytics, decision support tools and actionable knowledge to end-users over the Internet. Mr. Pratap has co-authored several pioneering technical papers/research reports for very prestigious publications and two international patents.

Rajiv was a founding member of Virtual Gold, Inc. (www.virtualgold.com) , a NY based data mining and BI company, and Avita Software Pvt. Ltd. He also served as the CTO of ChiMatrix, LLC (www.avitasoftware.com), a NY based company that focused on electronic data capture and advanced analytics for the pharmaceutical domain.

Rajiv has been educated at the Indian Institute of Technology, Kanpur, India (B. Tech., Computer Science, 1993).

Specialties: AI, Machine Learning, Deep Learning, Big Data, Knowledge discovery, data mining, advanced analytics, cognitive workflow automation for sales and marketing enablement.

closepopup
Mark PunyanityaFounder and CEO PhenoMX

Mark Punyanitya is a Biomedical Engineer with advanced degrees in Applied Physiology & Applied Clinical Trials. He facilitates the translation of science, technology, & medicine for development & commercialization of innovative technologies.

Co-Founder, President, & CEO of PhenoMx, Inc.: commercializing a Digital Physical Exam as an imaging platform that provides clinical & quantitative screening/diagnostic imaging to non-radiologists via extending these capabilities beyond the hospital into the community, to address the digital divide, health disparities, and social determinants of health.

With over 20 years experience implementing & standardizing medical imaging, Mark has published over 40 papers & his advances in body composition have been applied to a wide range of therapeutic areas.

Mark PunyanityaFounder and CEO PhenoMX

Mark Punyanitya is a Biomedical Engineer with advanced degrees in Applied Physiology & Applied Clinical Trials. He facilitates the translation of science, technology, & medicine for development & commercialization of innovative technologies.

Co-Founder, President, & CEO of PhenoMx, Inc.: commercializing a Digital Physical Exam as an imaging platform that provides clinical & quantitative screening/diagnostic imaging to non-radiologists via extending these capabilities beyond the hospital into the community, to address the digital divide, health disparities, and social determinants of health.

With over 20 years experience implementing & standardizing medical imaging, Mark has published over 40 papers & his advances in body composition have been applied to a wide range of therapeutic areas.

closepopup
Sanket Mishra, MPharma, MS, PhDCo-founder and Chief Scientific Officer at Grannus Therapeutics

Sanket Mishra, MPharma, MS, PhD, is a Co-founder and Chief Scientific Officer at Grannus Therapeutics. Grannus is developing of safer anticancer medicines by inhibiting Hsp90 isoforms. Dr. Mishra received his PhD from Kansas University and a postdoctoral fellowship at the University of Notre Dame and has a broad knowledge of pharmaceutics, chemistry, pharmacology, biochemistry and computational techniques. Dr, Mishra has over 10 years of experience in the pharmaceuticals and medicinal chemistry, and a proven track record of driving the advancement of drug discovery programs. His goal is to contribute and/or invent novel medicines by applying innovative synthetic chemistry, analytical techniques and data analysis to design and synthesize drug candidates and intermediates. Over the years, he has acquired experimental and theoretical knowledge of formulation sciences, pharmacology, biochemistry, pharmacognosy, anatomy, pathophysiology, physical and analytical chemistry, microbiology and biotechnology. He has discovered multiple first-in-class isoform-selective Hsp90 inhibitory scaffolds using a structure-based drug design approach that will lead to safer anti-cancer drugs. Furthermore, he has contributed to multiple publications, presentations and patents (three patents filed for the discovered isoform-selective Hsp90 inhibitor scaffolds with a few more in preparation). Over the years, he has provided scientific mentoring and technical training to several scientists and has been instrumental His expertise includes, basic analytical and structural data analysis and trouble-shooting synthetic routes to target molecules. Dr. Mishra has contributed in drug discovery for many therapeutic areas and has been instrumental is driving collaborations with thought leaders and KOLs.

Sanket Mishra, MPharma, MS, PhDCo-founder and Chief Scientific Officer at Grannus Therapeutics

Sanket Mishra, MPharma, MS, PhD, is a Co-founder and Chief Scientific Officer at Grannus Therapeutics. Grannus is developing of safer anticancer medicines by inhibiting Hsp90 isoforms. Dr. Mishra received his PhD from Kansas University and a postdoctoral fellowship at the University of Notre Dame and has a broad knowledge of pharmaceutics, chemistry, pharmacology, biochemistry and computational techniques. Dr, Mishra has over 10 years of experience in the pharmaceuticals and medicinal chemistry, and a proven track record of driving the advancement of drug discovery programs. His goal is to contribute and/or invent novel medicines by applying innovative synthetic chemistry, analytical techniques and data analysis to design and synthesize drug candidates and intermediates. Over the years, he has acquired experimental and theoretical knowledge of formulation sciences, pharmacology, biochemistry, pharmacognosy, anatomy, pathophysiology, physical and analytical chemistry, microbiology and biotechnology. He has discovered multiple first-in-class isoform-selective Hsp90 inhibitory scaffolds using a structure-based drug design approach that will lead to safer anti-cancer drugs. Furthermore, he has contributed to multiple publications, presentations and patents (three patents filed for the discovered isoform-selective Hsp90 inhibitor scaffolds with a few more in preparation). Over the years, he has provided scientific mentoring and technical training to several scientists and has been instrumental His expertise includes, basic analytical and structural data analysis and trouble-shooting synthetic routes to target molecules. Dr. Mishra has contributed in drug discovery for many therapeutic areas and has been instrumental is driving collaborations with thought leaders and KOLs.

closepopup
Sam King, MPHCOO at Medical Intelligence 10 (mi10)

Sam King MPH is an accomplished healthcare executive, faculty and consultant with unique combination of expertise in healthcare finance, healthcare IT, analytics, artificial intelligence, project management, financial planning and analysis, and continuous quality improvement; Strong leadership capability, exceptional organizational and project management skills with proven track record; Effective communication skills to manage expectations of internal and external clients, including physicians, clinicians, government agents and business executives; Demonstrated ability to manage project, direct and motivate multi-functional, multi-divisional teams; A frequent, internationally recognized speaker/moderator concerning current issues and challenges impacting health policy, healthcare IT, healthcare finance and quality.

Roles: CIO, COO, VP of Analytics, Director of Medical/Healthcare Informatics, Senior Director of Professional Development

Specialties: Healthcare Finance, Health IT, Artificial Intelligence, Big Data and Analytics, Process/Quality Improvement, Artifitial Intelligence, and Project Management

Sam King, MPHCOO at Medical Intelligence 10 (mi10)

Sam King MPH is an accomplished healthcare executive, faculty and consultant with unique combination of expertise in healthcare finance, healthcare IT, analytics, artificial intelligence, project management, financial planning and analysis, and continuous quality improvement; Strong leadership capability, exceptional organizational and project management skills with proven track record; Effective communication skills to manage expectations of internal and external clients, including physicians, clinicians, government agents and business executives; Demonstrated ability to manage project, direct and motivate multi-functional, multi-divisional teams; A frequent, internationally recognized speaker/moderator concerning current issues and challenges impacting health policy, healthcare IT, healthcare finance and quality.

Roles: CIO, COO, VP of Analytics, Director of Medical/Healthcare Informatics, Senior Director of Professional Development

Specialties: Healthcare Finance, Health IT, Artificial Intelligence, Big Data and Analytics, Process/Quality Improvement, Artifitial Intelligence, and Project Management

closepopup
Mohan UttarwarCEO at iNDx Technology, Inc.

Mohan Uttarwar is the co-founder and CEO of iNDX.AI, a silicon valley based Healthcare Informatics Company focusing on Translation Research in Oncology using AI/ML/NLP technologies. He is a serial entrepreneur with over 30 years of experience in successfully founding, establishing and exiting high-tech and Biotech start-ups in Silicon Valley, raising over $50M in funding and generating over $500M in shareholder value. He is an Angel Investor & serves on the BOD of Hemex Health, a very innovative point of care Malaria & Sickle cell Diagnostics Company. Mohan has joined Stanford University Medical School as a Research Scholar to work on developing new Socio-Economic business models that leverage innovation in affordable medical technology and transform the Health Care at the bottom of the pyramid in developing world, touching Billion Lives and creating Millions of jobs at the Micro & Macro levels. Mohan was the cofounder and CEO of iNDx LifeCare, next generation Point of Care Company, Oncomdx, an innovative Cancer Diagnostics company, which specialized, in integrated diagnostics (acquired by Core Diagnostics 2013). Mohan was the cofounder and CEO of BioImagene, a pioneer in Digital Pathology that was acquired by Roche in 2010 for $100M. He was the co-founder and CEO of Roamware Inc., a leading wireless roaming software company (acquired by Audax for $135M). He was also the cofounder and CEO of SoftPlus, an early provider of eCRM software for telecom carriers around the world. In March 2000, SoftPlus was sold to US Interactive for $360 million. Before starting SoftPlus, Mohan co-founded and served as the CEO of Digital Tools Inc., a leader in enterprise project and resource management software (Acquired by Toofan, Inc.). He previously held various software development and management positions with Hewlett Packard and Intel Corporation.
Mohan holds a Masters Degree in Computer Science from the Florida Institute of Technology and a Masters Degree in Electrical Engineering from Bombay University, and attended and advanced Management Program at Stanford University. He is a charter member of TiE (The Indus Entrepreneurs), a Silicon Valley-based forum for entrepreneurs. He is on the board of several non-profit organizations such as EPPIC: Association of Biotech and Pharma Executives; IDE - a leading non-profit devoted to the eradication of rural poverty worldwide; Drev – design revolution for the other 90% and DPA – Digital Pathology Association.
He lives in Cupertino California with his wife and 2 children, has run a marathon and Triathlon, is an avid trekker (trekked in all 7 continents, including Mt Kailash, Everest Base Camp (Himalayas), Kilimanjaro, Machu Picchu, Mont Blanc) and biked around Lake Tahoe (Tahoe Century) to help fund raising for cancer research.

Mohan UttarwarCEO at iNDx Technology, Inc.

Mohan Uttarwar is the co-founder and CEO of iNDX.AI, a silicon valley based Healthcare Informatics Company focusing on Translation Research in Oncology using AI/ML/NLP technologies. He is a serial entrepreneur with over 30 years of experience in successfully founding, establishing and exiting high-tech and Biotech start-ups in Silicon Valley, raising over $50M in funding and generating over $500M in shareholder value. He is an Angel Investor & serves on the BOD of Hemex Health, a very innovative point of care Malaria & Sickle cell Diagnostics Company. Mohan has joined Stanford University Medical School as a Research Scholar to work on developing new Socio-Economic business models that leverage innovation in affordable medical technology and transform the Health Care at the bottom of the pyramid in developing world, touching Billion Lives and creating Millions of jobs at the Micro & Macro levels. Mohan was the cofounder and CEO of iNDx LifeCare, next generation Point of Care Company, Oncomdx, an innovative Cancer Diagnostics company, which specialized, in integrated diagnostics (acquired by Core Diagnostics 2013). Mohan was the cofounder and CEO of BioImagene, a pioneer in Digital Pathology that was acquired by Roche in 2010 for $100M. He was the co-founder and CEO of Roamware Inc., a leading wireless roaming software company (acquired by Audax for $135M). He was also the cofounder and CEO of SoftPlus, an early provider of eCRM software for telecom carriers around the world. In March 2000, SoftPlus was sold to US Interactive for $360 million. Before starting SoftPlus, Mohan co-founded and served as the CEO of Digital Tools Inc., a leader in enterprise project and resource management software (Acquired by Toofan, Inc.). He previously held various software development and management positions with Hewlett Packard and Intel Corporation.
Mohan holds a Masters Degree in Computer Science from the Florida Institute of Technology and a Masters Degree in Electrical Engineering from Bombay University, and attended and advanced Management Program at Stanford University. He is a charter member of TiE (The Indus Entrepreneurs), a Silicon Valley-based forum for entrepreneurs. He is on the board of several non-profit organizations such as EPPIC: Association of Biotech and Pharma Executives; IDE - a leading non-profit devoted to the eradication of rural poverty worldwide; Drev – design revolution for the other 90% and DPA – Digital Pathology Association.
He lives in Cupertino California with his wife and 2 children, has run a marathon and Triathlon, is an avid trekker (trekked in all 7 continents, including Mt Kailash, Everest Base Camp (Himalayas), Kilimanjaro, Machu Picchu, Mont Blanc) and biked around Lake Tahoe (Tahoe Century) to help fund raising for cancer research.

closepopup
Tatyana KanzaveliFounder and CEO of Open Health Network

Tatyana Kanzaveli has gone from a programmer to senior executive at Big 5 to founder and CEO of a startup company along her 20 year career,recognized as a thought leader, mentor for her ability to guide Fortune 500 and startup companies through business challenges.
She’s worked for major companies like PricewaterhouseCoopers and Fujitsu and startups in the early days of the Web.
Tatyana has personally helped companies jump from 0 to millions in revenue even during the toughest economic times. She opened new verticals and markets.
Today she is the founder and CEO of Open Health Network, the startup in a Big Data/Healthcare space. She is a mentor at 500Startups and Richard Branson Entrepreneurs Centre and serves on boards for private companies. She also is licensee and organizer of highly notable TEDxBayArea conferences, she is a frequent speaker at US and International conferences on innovation, entrepreneurship and digital health.
Tatyana has been featured in the White House blog , spoke at the United Nations, presented at the first White House Demo Day hosted by the President Obama.
Tatyana has been recognized as one of the top 10 Influential Women in Healthcare IT in 2015.
Tatyana was USSR chess champion, played in the same team with Gary Kasparov, she loves to cook and kayak.

Tatyana KanzaveliFounder and CEO of Open Health Network

Tatyana Kanzaveli has gone from a programmer to senior executive at Big 5 to founder and CEO of a startup company along her 20 year career,recognized as a thought leader, mentor for her ability to guide Fortune 500 and startup companies through business challenges.
She’s worked for major companies like PricewaterhouseCoopers and Fujitsu and startups in the early days of the Web.
Tatyana has personally helped companies jump from 0 to millions in revenue even during the toughest economic times. She opened new verticals and markets.
Today she is the founder and CEO of Open Health Network, the startup in a Big Data/Healthcare space. She is a mentor at 500Startups and Richard Branson Entrepreneurs Centre and serves on boards for private companies. She also is licensee and organizer of highly notable TEDxBayArea conferences, she is a frequent speaker at US and International conferences on innovation, entrepreneurship and digital health.
Tatyana has been featured in the White House blog , spoke at the United Nations, presented at the first White House Demo Day hosted by the President Obama.
Tatyana has been recognized as one of the top 10 Influential Women in Healthcare IT in 2015.
Tatyana was USSR chess champion, played in the same team with Gary Kasparov, she loves to cook and kayak.

closepopup
Andre WatsonFounder, CEO Ligandal

Andre founded Ligandal to enable programming of biological matter with nanomaterials, ultimately with the aim of extending human lives and creating curative genomic therapies. While studying Biomedical Engineering and Biomaterials at RPI, he created a proof of concept for Ligandal's nanoparticle-based gene delivery platform, and the world’s first non-viral system for delivering guided nucleases in vivo. Andre created the proof of concept for the first technology capable of cell-specifically targeting gene editing constructs. Andre splits his attention between financing, business development, IP and designing biomimetic nanoparticle architectures. His vision for Ligandal is to enable a new era in personalized medicine and globally accessible gene therapy.

Andre WatsonFounder, CEO Ligandal

Andre founded Ligandal to enable programming of biological matter with nanomaterials, ultimately with the aim of extending human lives and creating curative genomic therapies. While studying Biomedical Engineering and Biomaterials at RPI, he created a proof of concept for Ligandal's nanoparticle-based gene delivery platform, and the world’s first non-viral system for delivering guided nucleases in vivo. Andre created the proof of concept for the first technology capable of cell-specifically targeting gene editing constructs. Andre splits his attention between financing, business development, IP and designing biomimetic nanoparticle architectures. His vision for Ligandal is to enable a new era in personalized medicine and globally accessible gene therapy.

closepopup
Ramesh Hariharan, PhD, MBAGeneral Manager of Women's Health business at Natera

Dr. Ramesh Hariharan’s career of 18 years spans a rage of subspecialties, including basic research, strategic management consulting, and marketing. At GE’s Basic Research Center, he was nominated as the Best Young Scientist for his innovations, which included the discovery of a new molecule that was commercialized to enable higher data densities in rewritable DVDs, and a novel process for agglomerating nanoparticles. At McKinsey, he served biotech, pharma, medical device, diagnostics, and private equity leaders in the U.S., Germany, and the U.K., tackling a wide range of business issues such as product launches, market expansion, life cycle strategies, and business turnarounds. Dr. Hariharan then held marketing leadership positions in Oncology, Women’s Health, and Vaccines at Novartis, Abbott/AbbVie and Biotheranostics. Most recently at Biotheranostics, he drove the successful commercial turnaround and relaunch of Breast Cancer Index and CancerTYPE ID including repositioning, branding, messaging, and targeted promotions to medical oncologists and patients. He received a bachelor’s degree in chemical engineering from IIT Bombay, a Ph.D. in chemical engineering from Princeton University, and an M.B.A. from MIT Sloan School of Management.

Ramesh Hariharan, PhD, MBAGeneral Manager of Women's Health business at Natera

Dr. Ramesh Hariharan’s career of 18 years spans a rage of subspecialties, including basic research, strategic management consulting, and marketing. At GE’s Basic Research Center, he was nominated as the Best Young Scientist for his innovations, which included the discovery of a new molecule that was commercialized to enable higher data densities in rewritable DVDs, and a novel process for agglomerating nanoparticles. At McKinsey, he served biotech, pharma, medical device, diagnostics, and private equity leaders in the U.S., Germany, and the U.K., tackling a wide range of business issues such as product launches, market expansion, life cycle strategies, and business turnarounds. Dr. Hariharan then held marketing leadership positions in Oncology, Women’s Health, and Vaccines at Novartis, Abbott/AbbVie and Biotheranostics. Most recently at Biotheranostics, he drove the successful commercial turnaround and relaunch of Breast Cancer Index and CancerTYPE ID including repositioning, branding, messaging, and targeted promotions to medical oncologists and patients. He received a bachelor’s degree in chemical engineering from IIT Bombay, a Ph.D. in chemical engineering from Princeton University, and an M.B.A. from MIT Sloan School of Management.

closepopup
Nazneen Aziz, PhDPresident and CEO, Variant Genomics, Inc

Nazneen Aziz is president and CEO of Varient Genomics. She was the former Executive Director of the Kaiser Permanente Research Bank (KPRB). Where she was responsible for strategic direction and operations of KPRB. Her pevious roles, Dr. Aziz was the SVP and Chief Research Officer at Phoenix Children’s Hospital, Director of Molecular Medicine at the College of American Pathologists (CAP). During her tenure at CAP, she led the development of the first set of standards and proficiency tests for clinical laboratories using next-generation sequencing. Dr. Aziz held executive leadership positions in the biotech/biopharma industry where she focused on personalized medicine, genetic tests, and development of drugs for cancer and diabetes. In her academic career, Dr. Aziz was an Assistant Professor at Harvard Medical School and Boston Children’s Hospital. Dr. Aziz received her Ph.D (molecular genetics) and MS (biochemistry) at MIT. Her publications have been cited extensively in the medical and scientific literature and she has been invited to speak at numerous national and international conferences.

Nazneen Aziz, PhDPresident and CEO, Variant Genomics, Inc

Nazneen Aziz is president and CEO of Varient Genomics. She was the former Executive Director of the Kaiser Permanente Research Bank (KPRB). Where she was responsible for strategic direction and operations of KPRB. Her pevious roles, Dr. Aziz was the SVP and Chief Research Officer at Phoenix Children’s Hospital, Director of Molecular Medicine at the College of American Pathologists (CAP). During her tenure at CAP, she led the development of the first set of standards and proficiency tests for clinical laboratories using next-generation sequencing. Dr. Aziz held executive leadership positions in the biotech/biopharma industry where she focused on personalized medicine, genetic tests, and development of drugs for cancer and diabetes. In her academic career, Dr. Aziz was an Assistant Professor at Harvard Medical School and Boston Children’s Hospital. Dr. Aziz received her Ph.D (molecular genetics) and MS (biochemistry) at MIT. Her publications have been cited extensively in the medical and scientific literature and she has been invited to speak at numerous national and international conferences.

closepopup
Sanjit Singh Dang, PhDFounder, U First Capital, Ex-Intel Capital, Advisor, Google

Sanjit Singh Dang, PhD, has been a successful Venture Capitalist, Corporate Executive, Board Member, Speaker and Writer in Silicon Valley for almost two decades. He is currently the Co-Founder and Chairman of U First Capital which provides Venture Capital as a Service to Corporations. Till 2018, he was at Intel Capital where he had an excellent track record of driving 1 Exit every year: DocuSign (IPO 2018), Body Labs (Acquired by Amazon in 2017), VokeVR (Acquired by Intel in 2016), Maginatics (Acquired by EMC in 2015) and Basis Science (Acquired by Intel in 2014). He has been an Investor and Board Member of several companies, including True Fit (AI for eCommerce, raised $100M), Reflektion (AI recommendation for eCommerce, raised $42M), Helpshift (AI-driven Customer Service, raised $39M) and Enlighted (IoT, Acquired by Siemens in 2018). He is also an investor in Mirantis (Cloud Computing), GoodData (SaaS BI) and Arcadia Data (Big Data 2.0).
Sanjit has experience investing in Consumer and Enterprise sectors across several areas: Transportation, Artificial Intelligence, Security, Big Data, IoT, Virtual Reality, eCommerce, etc.
Sanjit has been an Advisor to Richard Branson’s Extreme Tech Challenge and Google Launchpad. Sanjit has been on Hillary Clinton's Tech/Innovation Policy Advisory team. He is on Advisory Council of UN’s World Artificial Intelligence Organization. He has also been on University of California President's Innovation Council. Sanjit has the fastest Eng PhD from University of Illinois (2yrs 9mo after undergrad), which he received in 2000 with top research awards. He also attended the VC Executive program at Haas School of Business, UC Berkeley. He’s an invited Speaker at several top conferences, eg SURGE/WebSummit, TiECon, ShopTalk, McKinsey Leadership Summit, Silicon Valley Open Doors, Global AI conference, etc. He’s a mentor at Stanford and Berkeley’s Entrepreneurship programs.

Sanjit Singh Dang, PhDFounder, U First Capital, Ex-Intel Capital, Advisor, Google

Sanjit Singh Dang, PhD, has been a successful Venture Capitalist, Corporate Executive, Board Member, Speaker and Writer in Silicon Valley for almost two decades. He is currently the Co-Founder and Chairman of U First Capital which provides Venture Capital as a Service to Corporations. Till 2018, he was at Intel Capital where he had an excellent track record of driving 1 Exit every year: DocuSign (IPO 2018), Body Labs (Acquired by Amazon in 2017), VokeVR (Acquired by Intel in 2016), Maginatics (Acquired by EMC in 2015) and Basis Science (Acquired by Intel in 2014). He has been an Investor and Board Member of several companies, including True Fit (AI for eCommerce, raised $100M), Reflektion (AI recommendation for eCommerce, raised $42M), Helpshift (AI-driven Customer Service, raised $39M) and Enlighted (IoT, Acquired by Siemens in 2018). He is also an investor in Mirantis (Cloud Computing), GoodData (SaaS BI) and Arcadia Data (Big Data 2.0).
Sanjit has experience investing in Consumer and Enterprise sectors across several areas: Transportation, Artificial Intelligence, Security, Big Data, IoT, Virtual Reality, eCommerce, etc.
Sanjit has been an Advisor to Richard Branson’s Extreme Tech Challenge and Google Launchpad. Sanjit has been on Hillary Clinton's Tech/Innovation Policy Advisory team. He is on Advisory Council of UN’s World Artificial Intelligence Organization. He has also been on University of California President's Innovation Council. Sanjit has the fastest Eng PhD from University of Illinois (2yrs 9mo after undergrad), which he received in 2000 with top research awards. He also attended the VC Executive program at Haas School of Business, UC Berkeley. He’s an invited Speaker at several top conferences, eg SURGE/WebSummit, TiECon, ShopTalk, McKinsey Leadership Summit, Silicon Valley Open Doors, Global AI conference, etc. He’s a mentor at Stanford and Berkeley’s Entrepreneurship programs.

closepopup
Doug Milikien, MSPrincipal Consulting Biostatistician, NCC-ACRP

Involved in pharmaceutical, medical device, biologics, and diagnostic development for over 25 years, Doug began his postgraduate career as a Research Statistician with the Northern California Alzheimer’s Disease Center. After two years working for a statistical consulting firm, Doug founded Accudata Solutions in 1991. He has led or participated in numerous regulatory submissions and successfully interacted with regulatory bodies, including submissions for digital health and AI-driven products. Doug has served as a voting member of a Data Safety Monitoring Board and served as instructor to pharmaceutical scientists at the Institute for International Research as well as in-house instructor to the biotechnology division of a large, multinational pharmaceutical company. Doug serves as the statistics Subject Matter Expert and advisor for 2 mentoring programs offering guidance to start-up biotech and medical technology companies: a.) the California Life Science Institute’s FAST program, b.) and Canadian Technology Accelerator- San Francisco. He is the author of numerous peer-reviewed articles. Doug holds advanced degrees in Biostatistics and Demography, both from the University of California, Berkeley.

Doug Milikien, MSPrincipal Consulting Biostatistician, NCC-ACRP

Involved in pharmaceutical, medical device, biologics, and diagnostic development for over 25 years, Doug began his postgraduate career as a Research Statistician with the Northern California Alzheimer’s Disease Center. After two years working for a statistical consulting firm, Doug founded Accudata Solutions in 1991. He has led or participated in numerous regulatory submissions and successfully interacted with regulatory bodies, including submissions for digital health and AI-driven products. Doug has served as a voting member of a Data Safety Monitoring Board and served as instructor to pharmaceutical scientists at the Institute for International Research as well as in-house instructor to the biotechnology division of a large, multinational pharmaceutical company. Doug serves as the statistics Subject Matter Expert and advisor for 2 mentoring programs offering guidance to start-up biotech and medical technology companies: a.) the California Life Science Institute’s FAST program, b.) and Canadian Technology Accelerator- San Francisco. He is the author of numerous peer-reviewed articles. Doug holds advanced degrees in Biostatistics and Demography, both from the University of California, Berkeley.

closepopup
Suraj Saksena, PhDScience and Technology Leader, BD

Suraj Saksena, PhD is a team Lead/Senior Scientist: 14 years of experience in conducting scientific research including 3 years of experience working in drug discovery and 2 years of experience working in medical diagnostics in the Biotech industry. He has an excellent track record of obtaining scientific funding for conducting research. He is highly accomplished scientist with an excellent track record of obtaining research funding and mentoring junior scientists. He is an author of 14 peer-reviewed publications in top-rated scientific journals. PhD in Biochemistry from Texas A&M University.

Suraj Saksena, PhDScience and Technology Leader, BD

Suraj Saksena, PhD is a team Lead/Senior Scientist: 14 years of experience in conducting scientific research including 3 years of experience working in drug discovery and 2 years of experience working in medical diagnostics in the Biotech industry. He has an excellent track record of obtaining scientific funding for conducting research. He is highly accomplished scientist with an excellent track record of obtaining research funding and mentoring junior scientists. He is an author of 14 peer-reviewed publications in top-rated scientific journals. PhD in Biochemistry from Texas A&M University.

closepopup
Sanjeev Jain, MD, PhDCEO, The Columbia Asthma & Allergy Clinic

Educated in allergy and immunology at Yale University, Dr. Jain first received a joint MD and PhD from the University of Wisconsin and finished his residency at the University of Texas. He then taught and practiced at the University of Washington Medical School in Seattle, where he developed a reputation as one of the finest allergists in the region. He has won numerous awards and is included in the Guide to America’s Top Physicians consistently for last several years.
As an allergist, Dr. Jain treasures the opportunity to witness his patients make dramatic improvements after years of suffering.
He can recall several instances where his patients who had previously required repeated hospital admissions for asthma exacerbations have returned to normal lives free of hospitalizations. In Dr. Jain’s experience, most patients can achieve significant improvements by determining the individual triggers of their allergic reactions and by instituting an appropriate therapy. “Any type of symptom, is not acceptable.”
Dr. Jain’s OIT experience spans back to 2007. He has developed protocols that permit a patient to move through the entire desensitization process with little to no side effects using little to no additional medications. In simple terms, Dr. Jain can treat any food allergy and is one of the few OIT Allergists to offer SLIT therapy as well as traditional OIT.

Sanjeev Jain, MD, PhDCEO, The Columbia Asthma & Allergy Clinic

Educated in allergy and immunology at Yale University, Dr. Jain first received a joint MD and PhD from the University of Wisconsin and finished his residency at the University of Texas. He then taught and practiced at the University of Washington Medical School in Seattle, where he developed a reputation as one of the finest allergists in the region. He has won numerous awards and is included in the Guide to America’s Top Physicians consistently for last several years.
As an allergist, Dr. Jain treasures the opportunity to witness his patients make dramatic improvements after years of suffering.
He can recall several instances where his patients who had previously required repeated hospital admissions for asthma exacerbations have returned to normal lives free of hospitalizations. In Dr. Jain’s experience, most patients can achieve significant improvements by determining the individual triggers of their allergic reactions and by instituting an appropriate therapy. “Any type of symptom, is not acceptable.”
Dr. Jain’s OIT experience spans back to 2007. He has developed protocols that permit a patient to move through the entire desensitization process with little to no side effects using little to no additional medications. In simple terms, Dr. Jain can treat any food allergy and is one of the few OIT Allergists to offer SLIT therapy as well as traditional OIT.

closepopup
Subhadra Dravida, PhDFounder and CEO, Transcell Biologics

Subhadra Dravida, PhD is the founder CEO of Transcell Biologics Pvt. Ltd www.transcellbio.science, innovating new vistas in healthcare/biotechnology industry and markets from India. She is an entrepreneurial technocrat of global standing having worked in the USA, Canada and India in the domains of stem cell research/biobanking and product development. She has unique blend of skills of wet lab, product development to managing business. Under her stewardship, Transcell Biologics, a knowledge driven technology intensive entity has evolved from its inception as an R&D unit to a fully integrated biotechnology enterprise encompassing a well balanced business portfolio offering indigenous technologies on biobanking and processing services with drug discovery research integrating regenerative medicine into clinical practice.
She is a biologist by education with clinical informatics research experience having associated professionally with the University of North Carolina, USA, Ottawa Health Research Institute, Canada. S Dravida has peer reviewed publications and patents to her credit and was nominated for global women in leadership award in 2011 in science, recipient of 2012, Small Business Industrial Research award to develop dental stem cell products/processes in implantology, MSME award to conduct research on lacrimal gland regeneration to address dry eye syndrome, PPMD support to craft stem cell treatment protocols treating Muscular Dystrophies, in 2012-14. She is the recipient of 2017 Lady Entrepreneur Award given by GOI. She holds IP in the field of large scale cell productions & novel druggable formulations. Outside of work, she explores Monasteries, night skies and reads Science fiction.

Subhadra Dravida, PhDFounder and CEO, Transcell Biologics

Subhadra Dravida, PhD is the founder CEO of Transcell Biologics Pvt. Ltd www.transcellbio.science, innovating new vistas in healthcare/biotechnology industry and markets from India. She is an entrepreneurial technocrat of global standing having worked in the USA, Canada and India in the domains of stem cell research/biobanking and product development. She has unique blend of skills of wet lab, product development to managing business. Under her stewardship, Transcell Biologics, a knowledge driven technology intensive entity has evolved from its inception as an R&D unit to a fully integrated biotechnology enterprise encompassing a well balanced business portfolio offering indigenous technologies on biobanking and processing services with drug discovery research integrating regenerative medicine into clinical practice.
She is a biologist by education with clinical informatics research experience having associated professionally with the University of North Carolina, USA, Ottawa Health Research Institute, Canada. S Dravida has peer reviewed publications and patents to her credit and was nominated for global women in leadership award in 2011 in science, recipient of 2012, Small Business Industrial Research award to develop dental stem cell products/processes in implantology, MSME award to conduct research on lacrimal gland regeneration to address dry eye syndrome, PPMD support to craft stem cell treatment protocols treating Muscular Dystrophies, in 2012-14. She is the recipient of 2017 Lady Entrepreneur Award given by GOI. She holds IP in the field of large scale cell productions & novel druggable formulations. Outside of work, she explores Monasteries, night skies and reads Science fiction.

closepopup
Manoj KenkareManaging Director, Accenture

Manoj Kenkare is a seasoned executive and most Trusted advisor. He is well networked executive within SF bay area with relationships in North America and beyond. During his career Manoj has worked on several transformation deals with Fortune 100 companies and some key institutions like The Whitehouse, FDA, NIH and CDC. Key areas of focus Strategy, AI, SAP/Oracle/ERP applications, Analytics and Data Sciences, Mobility, Workday, Cloud and Portal strategies among others.

Manoj KenkareManaging Director, Accenture

Manoj Kenkare is a seasoned executive and most Trusted advisor. He is well networked executive within SF bay area with relationships in North America and beyond. During his career Manoj has worked on several transformation deals with Fortune 100 companies and some key institutions like The Whitehouse, FDA, NIH and CDC. Key areas of focus Strategy, AI, SAP/Oracle/ERP applications, Analytics and Data Sciences, Mobility, Workday, Cloud and Portal strategies among others.

closepopup
Douglas Zhang, MD, MBAPhysician and Managing Partner FMG

Dr. Douglas Zhang, MD is a family medicine specialist in San Leandro, CA and has been practicing for 25 years. He graduated from Texas Tech University Health Sciences Center School Of Medicine in 1994 and specializes in family medicine.

Douglas Zhang, MD, MBAPhysician and Managing Partner FMG

Dr. Douglas Zhang, MD is a family medicine specialist in San Leandro, CA and has been practicing for 25 years. He graduated from Texas Tech University Health Sciences Center School Of Medicine in 1994 and specializes in family medicine.

closepopup
David Purdie, PhDVice President, Proteus Digital Health

David Purdie, PhD is VP at Proteus Digital Health. Prior to Proteus he was at Genentech Roche, where he served as the head of quality of care and patient access as well as director of BioOncology commercial training and development. He was also a lecture at Stanford.

David Purdie, PhDVice President, Proteus Digital Health

David Purdie, PhD is VP at Proteus Digital Health. Prior to Proteus he was at Genentech Roche, where he served as the head of quality of care and patient access as well as director of BioOncology commercial training and development. He was also a lecture at Stanford.

closepopup

Schedule

AAPM 2021 Annual Meeting Plenary Session

  • January 8th
  • January 7th
  • Theater
04:30 PM - 05:15 PMPlenary Sessions AAPM Annual Meeting 2021 By VariousClinical Trials

Opening Keynotes: Driving the future of Precision Medicine

Session 1: New era in patient centric care with Precision Medicine

Session 2: Precision Medicine Barriers in drug development

Session 3: Role of Physicians Transforming personalized healthcare

Session 4: Patient Advocates in Precision Medicine

Closing Keynotes: How Precision Medicine is improving Quality of Care!

 

 

  • Theater
08:00 AM - 02:30 PMDataAI National Summit 2021 (DANS2021) By VariousClosing keynote

Opening keynotes: AI-The next revolution in healthcare and Precision medicine

Session 1: AI driven translational research

Session 2: Need of advance data capture- improve medicinal research

Session 3: AI diagnostic tools- impact on clinical practice and patient centric care

Session 4: Advances in novel Biotechnology derived therapies by AI

Closing Keynotes: Big Data challenges to facilitate implementation of Precision medicine approaches

Gold Ticket

$80/ person
  • Get Acess to all Sessions
  • Unlimited Coffee and Foods
  • Meet with Favourite Speakers
  • Access to all Audio and Video Files
  • Get Acess to all Sessions
DINESH KOTAK, MD
DINESH KOTAK, MDDINESH KOTAK, MD Chair- Departmental Technology Leads – Oncology, Kaiser Permanente

"Thanks Prasun, for invite and the award. It was a privilege to share the stage with such an accomplished and committed panel and an engaged and well-informed audience."

NISHIT DOSHI, PhD
NISHIT DOSHI, PhDDirector, Roche Molecular Systems

"Really enjoyed moderating the panel discussion on "New technologies and breakthroughs in cancer care" at the American Association of Precision Medicine. Excellent event, very well organized! Looking forward to the annual meeting."

PANKAJ BHARGAVA, MD
PANKAJ BHARGAVA, MDVP, Oncology TA Head Gilead Sciences, Former Professor Harvard Medical School

"Thanks all, honored to accept this award on behalf of our terrific teams at Gilead and Kite! Great forum!! Thanks Prasun and the AAPM team!"

GARY STARLING, PhD
GARY STARLING, PhDAssociate Vice President at Merck

“Pleased to have been able to accept this award on behalf of Merck's amazing Keytruda Clinical teams at the DANS meeting last week. [ ….] Congratulations to the Merck Oncology Clinical Development team.”

Get Your Tickets Today, Before they are Sold Out!

Days
Hours
Minutes
Seconds

FAQ’s

Commonly asked questions about the event.

Contact Us

Explore our pst events and enjoy!

Send Message

If you have any questions or just want to get in touch, use the form below. We look forward to hearing from you!

    AAPM 2020 is Hosted Virtually